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About This Column
Lawrence O. Gostin and
Benjamin Mason Meier serve
as the section editors for Global
Health Law. Professor Gostin is
University Professor at Georgetown
University and the Founding Linda
D. & Timothy J. O’Neill Professor of
Global Health Law at Georgetown
University Law Center and Director
of the World Health Organization
Center on National and Global
Health Law. Professor Meier is
an Associate Professor of Global
Health Policy at the University of
North Carolina at Chapel Hill and a
Scholar at the O’Neill Institute for
National and Global Health Law. This
column features timely analyses and
perspectives on law, policy, and justice
in global health.
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Threatening the entire world, the
burden of the COVID-19 pandemic
has continued to grow, with devastating effects on human health, social
connections, and economic livelihoods. These crushing burdens are
likely to increase dramatically as the
pandemic continues its relentless
march across the globe. Some governments have taken steps to mitigate the worst impacts of this threat
through aggressive public health
interventions — including diagnostic
testing, contact tracing, widespread
masking, and physical distancing
— but with the pandemic expected
to inflict unprecedented human suffering in the months ahead, it has
become clear that only a vaccine will
be able to contain the COVID-19
threat.
There has not been a more soughtafter medical resource in our lifetimes
than a safe and effective COVID-19
vaccine, and given this existential
threat, vaccine candidates will move
swiftly into clinical trials in the coming months. While vaccine development holds great promise, the discovery phase is only the first step.
Clinical trials may well demonstrate
that one or more vaccine candidates
is safe and effective, yet those vaccines must still be approved by regulatory authorities, manufactured and
distributed to scale, and made affordable for all. Depending on how these
issues are resolved, a prospective vaccine could heal the rifts of a bitterly
divided world, or it could exacerbate
them if countries hoard a necessary

vaccines and undermine equitable
access.
This column explores the global
health law reforms necessary to progressively realize universal access to a
future COVID-19 vaccine. We begin
by explaining the importance of
global health law in the distribution
of essential vaccines as a determinant
of public health. The column then
turns to examine the human rights
foundations of global health law, conceptualizing vaccination access as a
universal human right. We find that
it will be crucial to develop legal commitments to ensure vaccine access
prior to a scientific breakthrough,
analyzing the legal barriers that
impede global access and the global
health law reforms necessary to facilitate global solidarity.
Vaccination Access through
Global Governance
As governments have found themselves constrained in national efforts
to mitigate the pandemic, it appears
almost certain that COVID-19 will
not be controlled globally without the
development of a vaccine. An effective vaccine will be essential to limit
the spread of the SARS-CoV-2 virus,
prevent it from reoccurring, and bring
about the eventual containment of the
COVID-19 pandemic. Without lasting
protection from infection and population-level immunity, the world will
face higher transmission, repeated
outbreaks, and unnecessary deaths.1
Yet, these immunization benefits can
only be realized if there is sufficient
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access across all countries. If any country or region is left out, global protection remains at considerable risk.
Ensuring worldwide vaccination
coverage will require global governance. An effective vaccine should
be seen as a global public good,
with benefits shared by all nations
but requiring global cooperation to
guarantee its benefits.2 No country should hoard it. No corporation
should profit from it. And no institution or individual should own
intellectual property rights. Despite
the rise of “vaccine nationalism,” no

health law. Even if several vaccines
are approved in the coming year,
few low- and middle-income countries (LMICs) will have the capacity
to produce vaccines without affordable access to global supply chains.4
Determining how to distribute a vaccine within and across countries is a
global concern that cannot be decided
by a single nation or pharmaceutical
corporation.5 With so much global
competition, no government can be
sure its scientists or pharmaceutical
companies will be “first and best.” It is
now, before we know who will prevail

While vaccine development holds great promise,
the discovery phase is only the first step. Clinical
trials may well demonstrate that one or more
vaccine candidates is safe and effective, yet those
vaccines must still be approved by regulatory
authorities, manufactured and distributed to
scale, and made affordable for all. Depending
on how these issues are resolved, a prospective
vaccine could heal the rifts of a bitterly divided
world, or it could exacerbate them if countries
hoard necessary vaccines and undermine
equitable access.
country acting alone can assure success.3 Collaboration and coordination
are needed for every stage in vaccine
development and implementation:
scientific cooperation in discovery
and clinical trials, global manufacturing and distribution in sufficient
quantities, and equitable allocation
worldwide. We are unlikely ever
to eradicate SARS-CoV-2, but the
World Health Organization (WHO)
vaccination campaign that eradicated
smallpox demonstrates the need for
international cooperation, bringing
nations together to accomplish what
none can do alone.
Effective governance for vaccine
discovery, production, and distribution requires a coalition of state
and non-state actors through global
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in this vaccine competition, that we
must plan for equity.6 Global health
law reforms are necessary to assure
that a prospective vaccine is distributed fairly based upon global norms,
realizing vaccination as a universal
right.
Vaccination as a Human Right
Human rights law provides an international legal foundation for the progressive realization of vaccine access.
COVID-19 not only endangers health
and longevity, but does so inequitably
— burdening the poor, the sick, the
disadvantaged, and the marginalized.
Recognizing the equal dignity of all
persons, human rights law requires
equitable access to essential vaccines
for disease prevention and health
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promotion.7 A growing anti-vaccination movement is already mobilizing
under “rights” discourse to oppose
a prospective COVID-19 vaccine;8
however, this co-optation of human
rights rhetoric does not obviate
human rights obligations to ensure
access to essential medicines. In realizing the highest attainable standard
of health through vaccination, human
rights law provides an international
obligation to progressively realize the
prevention, treatment, and control of
prevalent diseases.
Access to an essential lifesaving
vaccine is a core human rights obligation. Immunization is science’s best
prevention tool and remains a quintessentially important element of the
right to the highest attainable standard of health.9 The United Nations
Special Rapporteur on the right to
health concluded that states are obligated to “do all they reasonably can
to make sure that existing medicines
are available in sufficient quantities.”10 The widespread provision of
a COVID-19 vaccination also finds
support under the human right to the
benefits of scientific progress, requiring that states provide resources for
the distribution of scientific progress,
remove discriminatory barriers, and
ensure access to the “most advanced,
up-to-date, and verifiable science
available.”11 In realizing these rights,
a COVID-19 vaccination, similar to
life saving antiretrovirals for HIV,
will almost certainly be classified by
WHO as an “essential medicine,” raising national and international obligations to ensure access.12
States bear international legal
obligations to progressively realize universal access to vaccines,
demanding that national resources
and international assistance move “as
expeditiously and effectively as possible towards the full realization” of
rights.13 To implement human rights
to a prospective COVID-19 vaccine,
states must ensure that any safe and
effective vaccination is:
• Available — requiring that states
provide sufficient quantities of
vaccine goods and services and
highlighting the importance of
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widespread production and rapid
distribution.
• Accessible — requiring that the
distribution of vaccines accounts
for obstacles faced by vulnerable
and marginalized populations,
ensuring a vaccine that is affordable, within safe physical reach,
and delivered with all necessary
information.
• Acceptable — requiring that this
essential intervention be respectful of medical ethics such as
informed consent and be designed
to account for distinct cultural considerations across populations.
• Of Sufficient Quality — requiring
that the vaccine be “scientifically
and medically appropriate and of
good quality,” avoiding counterfeit
and sub-standard vaccines and
employing skilled personal and
approved equipment.14
The implementation of human rights
to realize access to a COVID-19 vaccine will require the development
of new forms of global governance
through law.
Global Governance through
Global Health Law
The reform of global health law to
ensure universal access to a COVID19 vaccine will require: facilitating
funding and benefit sharing, easing
intellectual property protections,
and harmonizing national vaccine
regulations.
Funding and Benefit Sharing
Equitable access to a COVID-19 vaccine will hinge on its widespread production, global supply chains, accessibility, acceptability, and affordability.
Global governance could lower vaccine prices, ramp up industry production, and ensure global distribution, but existing Global Public/
Private Partnerships (GPPPs) lack
the legal accountability necessary to
ensure benefit sharing. Gavi, the Vaccine Alliance was the first GPPP to
use advanced market commitments
and bulk purchasing to secure lower
vaccine prices.15 To accelerate the
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development of new vaccines against
emerging infectious diseases, the
Coalition for Epidemic Preparedness
Innovations (CEPI) was launched to
facilitate access to new vaccines during outbreaks. With both Gavi and
CEPI repurposing to facilitate access
to a future COVID-19 vaccine, WHO
has joined them in establishing a new
GPPP, the COVID-19 Vaccine Global
Access (COVAX) Facility; however,
even with support from large donor
countries and foundations, these
GPPPs lack the legitimacy and funding with which to coordinate nationalist governments and pharmaceutical companies.16
There is a need to create a universal global health law mechanism to
ensure equitable benefit sharing, particularly for LMICs that have limited
access to new health technologies.
The WHO Pandemic Influenza Preparedness (PIP) Framework is the
only existing global mechanism to
obligate governments to share biological samples and genetic sequencing data needed to promote research.
The PIP Framework also promotes
equitable sharing of the benefits of
research. That Framework, however, only applies to pandemic influenza pathogens. 17 Although there
are a number of GPPPs to promote
knowledge-sharing in COVID-19
research,18 a binding framework for
equitable sharing will be needed to
prevent states from hoarding a prospective vaccine. New benefit sharing
agreements in global governance can
ensure that states act for the common
good, limit the commercialization of
publicly funded research, and support
equitable COVID-19 vaccine access.

maximize profit.19 As TRIPS made
life-saving medicines unaffordable in
LMICs, the 2001 WTO Doha Declaration sought to create “flexibilities”
to limit IP protections to protect public health.20 However, these measures
to support affordable medicines cannot easily be translated to vaccines.
Compulsory licensing can remove IP
barriers for the production of generic
medicines, but in the context of vaccines, these IP flexibilities cannot
address the shortage of infrastructure, capacity, technical knowledge,
and regulatory recognition necessary
for generic vaccines.21
Making vaccines affordable
requires increasing vaccine manufacturing capacity in LMIC and
providing new legal mechanisms to
share technical production processes.
Understanding protections on production processes — not only final
products — will be crucial to making
a COVID-19 vaccine affordable. UNITAID and the Medicines Patent Pool
have successfully negotiated global
patent clearing houses to support the
production of affordable drugs.22 The
COVID-19 Technology Access Pool
(C-TAP) recognizes the complexity
of making vaccines affordable and
seeks to facilitate the sharing of data,
IP, and knowledge while compensating the patent holder.23 C-TAP could
play a critical role in making compulsory licenses feasible for a COVID-19,
vaccine but this voluntary system24
will require stronger enforcement
through global health law to ensure
widespread participation of public
and private actors and alignment of
international trade law with global
health imperatives.

Intellectual Property
The tensions between intellectual
property and public health could
also impede global access to a prospective COVID-19 vaccine. Under
World Trade Organization (WTO)
governance, the Agreement on
Trade-Related Aspects of Intellectual
Property Rights (TRIPS) allows for
the global enforcement of intellectual property (IP) rights. The TRIPS
agreement thus allows developers of
vaccines to enforce patent protections to monopolize production and

Vaccine Regulation
Finally, where the safety and effectiveness of a COVID-19 vaccine will
require approval in every country,
creating a patchwork of national regulatory obstacles, global health law is
necessary to harmonize and expedite
national vaccine regulations. In many
countries, national approval processes may be unduly burdensome
— and at times unnecessary if a stringent regulatory authority (like the
US FDA or the European Medicines
Agency) has already approved the
journal of law, medicine & ethics
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technology.25 Simultaneously, a lack
of regulatory capacity in some countries can delay rollout or allow falsified or substandard products to enter
the market.26 Despite WHO efforts
to harmonize national approval processes, national governments have
differing regulatory capacities to
evaluate and approve new drugs,
and vaccine approval processes have
remained slower than necessary in
many countries.27
Against this diverse national regu-

cines, global health law can support
efficient processes to regulate and
approve a safe and effective COVID19 vaccine.
Overcoming the World’s Greatest
Challenge
The COVID-19 response has proven
to be the greatest challenge the world
has faced in generations, and it can
be contained only if nations are willing and able to work together. Yet,
despite an imperative for collective

The COVID-19 response has proven to be
the greatest challenge the world has faced in
generations, and it can be contained only if
nations are willing and able to work together.
Yet, despite an imperative for collective action,
governments have scrambled to establish
nationalist legal agreements to hoard prospective
vaccines while dividing the world in ways that
will prolong the pandemic threat. Although
the barriers to global health coordination and
universal vaccine access remain complex, global
health law can support global solidarity in facing
this common threat, reaching agreements now to
secure equitable access to a hopeful new vaccine.
latory landscape, global health law
can support the regulation of new
vaccines in an efficient and effective
manner. The WHO Pre-Qualification
Process28 (PQP) can serve in place of
national regulations and streamline
regulatory approvals for a COVID19 vaccine — provided that states
introduce laws recognizing the PQP.
WHO has additionally recommended
the establishment of National Immunization Technical Advisory Groups
(NITAG) to provide evidence-based
advice on vaccines and immunization.29 NITAGs can support regulations for the financing and delivery
of prospective vaccines and prioritize public health and health equity
in vaccine access. By strengthening
national capacity to approve vac-
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action, governments have scrambled
to establish nationalist legal agreements to hoard prospective vaccines
while dividing the world in ways that
will prolong the pandemic threat.
Although the barriers to global health
coordination and universal vaccine
access remain complex, global health
law can support global solidarity in
facing this common threat, reaching
agreements now to secure equitable
access to a hopeful new vaccine.
Note
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